



Press release 2013-09-20

C-RAD has released Free Breathing Gating Solution for Elekta Linear Accelerators

C-RAD has released a solution for free breathing respiratory gating. The package offers gated treatments based on the C-RAD Catalyst technology for all digital Elekta linear accelerators.

The validation of C-RAD Catalyst with the Elekta Response 2 interface has successfully been finalized. Catalyst, as well as the C-RAD solution for 4DCT based on Sentinel technology is now accessible to clinicians worldwide.

C-RAD will roll out the new functionality in October. First installations and deliveries will start immediately thereafter on key markets in the US and Europe.

Respiratory gated treatments based on free breathing are frequently used when the target volume is close to cardiac tissue or for special treatments in which tumor position depends on the respiratory cycle. The Catalyst and Sentinel system offer the required technology to perform such high end treatment techniques within radiation therapy. With this solution C-RAD supports the whole 4D treatment chain from imaging to delivery.

Tim Thurn, CEO, C-RAD AB:

“I am very pleased to announce the integration of the C-RAD Catalyst with Elekta digital linear accelerators. I am confident it provides the best gating solution within the industry to clinics and RT Centers. We are excited to demonstrate these capabilities at the upcoming ASTRO exhibition.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD SentinelTM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com